It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Helicobacter pylori (Hp) Gram-negative bacteria cause gastritis or gastric ulcers. They may be involved in the development of systemic diseases i.e. coronary heart disease (CHD). Both Hp infection and CHD are related to inflammation accompanied by C-reactive protein (CRP), tumor necrosis factor alfa (TNF-α) and homocysteine. Low density lipoprotein (LDL) and triglicerides are a classic risk factors of CHD. Infrared spectroscopy has been introduced for monitoring chronic infections or endogenous disorders using specific absorption bands for biocomponents typed as diagnostic markers. In this study we selected specific motives of infrared radiation (IR) spectra for the sera from CHD patients infected with Hp. In total 141 sera were used: 90 from patients with CHD, all Hp positive, and 51 from healthy donors, 32 Hp negative and 21 Hp positive. Hp status was evaluated by anti-Hp IgG antibodies and/or 13C urea breath testing. IR spectra were measured using FT-IR/FT-NIR Spectrum 400 spectrometer (PerkinElmer) chemometrically analyzed using artificial neural networks and they showed differences in absorption bands corresponding to triglicerides, CRP, homocysteine, LDL and TNF-α, and selected component groups between CHD patients infected with Hp vs healthy uninfected donors (96.15% accuracy). Triglicerides and CRP were the best biomarkers linking Hp infection with CHD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Lodz, Department of Immunology and Infectious Biology, Faculty of Biology and Environmental Protection, Lodz, Poland (GRID:grid.10789.37) (ISNI:0000 0000 9730 2769); Jan Kochanowski University, Department of Synthesis and Structural Research, Faculty of Natural Sciences, Kielce, Poland (GRID:grid.411821.f) (ISNI:0000 0001 2292 9126)
2 Jan Kochanowski University, Departament of Microbiology, Faculty of Natural Sciences, Kielce, Poland (GRID:grid.411821.f) (ISNI:0000 0001 2292 9126)
3 Jan Kochanowski University, Department of Synthesis and Structural Research, Faculty of Natural Sciences, Kielce, Poland (GRID:grid.411821.f) (ISNI:0000 0001 2292 9126)
4 Medical University of Lodz, Clinic and Department of Cardiology, Lodz, Poland (GRID:grid.8267.b) (ISNI:0000 0001 2165 3025)
5 Medical University of Lodz, Department of Immunology and Allergy, Lodz, Poland (GRID:grid.8267.b) (ISNI:0000 0001 2165 3025)
6 Medical University of Lodz, Laboratory of Tissue Immunopharmacology, Department of Internal Diseases and Clinical Pharmacology, Lodz, Poland (GRID:grid.8267.b) (ISNI:0000 0001 2165 3025)
7 University of Lodz, Department of Immunology and Infectious Biology, Faculty of Biology and Environmental Protection, Lodz, Poland (GRID:grid.10789.37) (ISNI:0000 0000 9730 2769)